



Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting
December 3, 2008

Location: Iowa State Capitol Building
Room 116
Des Moines, Iowa 50319

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the minutes
2. Update Confidentiality Agreement
3. Iowa Medicaid Enterprise Update(s)
 - a) Discussion of P & T Committee recommendations relative to RDL drugs
 - b) PDL with changes
 - c) P & T Committee Meeting Minutes
 - d) Side Effect Comparison Summary
 - e) Drug Class Reviews
4. Case Reviews
5. Smoking Cessation
 - a) Smoking Cessation Report – Final Version
 - b) Presentation and Q&A from Disa Cornish (Univ. of Northern Iowa), Jeremy Whitaker & Bonnie Mapes (Iowa Department of Public Health) – Quitline Iowa participant satisfaction surveys and assessment of cessation
6. ProDUR Edits: Discuss expansion of *Quantity Limits List* to include most costly short acting narcotics and benzodiazepines
7. Focus Studies/Provider Education Initiatives
 - a) Anticonvulsant Drugs used in Mental Health Disorders – Initial Review of Utilization Data
 - b) Drugs used for Restless Leg Syndrome – Initial Review of Utilization Data
 - c) Chronic use of Mupirocin – Initial Review of Utilization Data
 - d) Duplicate SSRI Utilization – Initial Review of Utilization Data
8. Public Comment

9. Prior Authorization

- a) Sedative/Hypnotics – Non-Benzodiazepine – Update criteria following P&T Recommendations
- b) Incretin Mimetic (Byetta®) – Review existing clinical PA criteria at request of P&T Committee

10. Public Comment

11. Miscellaneous

- a) MedWatch
- b) Auralgan Otic CMS Notification
- c) Notification of FUL Updates

12. Executive Closed Session

- a) Approval of Minutes
- b) Member Profiles

13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Director, Chad Bissell, Pharm.D. at info@iadur.org or (515) 725-1271